Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:activities |
mimics natural insulin
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:availability |
widely available
|
| gptkbp:best_time_to_visit |
before meals
|
| gptkbp:brand |
gptkb:Humalog
gptkb:Novolog Apidra |
| gptkbp:clinical_trial |
type 2 diabetes
type 1 diabetes gestational diabetes extensively studied |
| gptkbp:contraindication |
severe liver disease
hypersensitivity to insulin |
| gptkbp:developer |
developed in the 1990s
|
| gptkbp:dosage_form |
individualized based on needs
|
| gptkbp:duration |
3 to 5 hours
|
| gptkbp:education |
monitor blood sugar regularly
recognize signs of hypoglycemia carry glucose tablets |
| gptkbp:form |
cartridges
pens vials |
| gptkbp:formulation |
clear solution
|
| gptkbp:healthcare |
gptkb:Person
adults elderly |
| gptkbp:highest_point |
1 to 2 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rapid-acting insulin
|
| gptkbp:interacts_with |
gptkb:ACE_inhibitors
beta-blockers thiazolidinediones |
| gptkbp:is_monitored_by |
requires regular blood glucose checks
|
| gptkbp:is_standardized_by |
gptkb:insulin_lispro
gptkb:insulin_aspart gptkb:insulin_glulisine |
| gptkbp:is_used_for |
diabetes management
|
| gptkbp:manager |
intravenous
subcutaneous |
| gptkbp:pharmacokinetics |
short duration of action
rapid absorption |
| gptkbp:premiered_on |
15 minutes
|
| gptkbp:price |
varies by brand
may be covered by insurance |
| gptkbp:regulatory_compliance |
FDA approved
|
| gptkbp:safety_features |
generally safe when used correctly
|
| gptkbp:side_effect |
weight gain
hypoglycemia |
| gptkbp:storage |
refrigerated
|
| gptkbp:sugar_content |
improves postprandial glucose levels
|
| gptkbp:bfsParent |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|